Pancreatic adenocarcinomas with mature blood vessels have better overall survival

Pancreatic ductal adenocarcinoma (PDAC) is known for its hypovascularity. Bevacizumab, an anti-angiogenic drug, added to standard chemotherapy demonstrated no improvement in outcome for PDAC. Therefore, we hypothesized that increased vascularity may be associated with improved outcomes in PDAC possi...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsuta, Eriko, Qi, Qianya, Peng, Xuan, Hochwald, Steven N., Yan, Li, Takabe, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362082/
https://www.ncbi.nlm.nih.gov/pubmed/30718678
http://dx.doi.org/10.1038/s41598-018-37909-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362082/
https://www.ncbi.nlm.nih.gov/pubmed/30718678
http://dx.doi.org/10.1038/s41598-018-37909-5

Ejemplares similares